After conducting an updated analysis, evaluation and investigation of reported cases, the FDA has determined that the risk of thrombosis with thrombocytopenia syndrome (TTS), a syndrome of rare and potentially life-threatening blood clots in combination with low levels of blood platelets with onset of symptoms approximately one to two weeks following administration of the Janssen COVID-19 Vaccine, warrants limiting the authorized use of the vaccine.
Imagine losing your son to a vaccine because of a disease which posed LESS risk to young people than influenza
Imagine losing your son to a vaccine because of a disease which posed LESS risk to young people than influenza